Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 318 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: amphetamine Clear all
Recruiting Phase 4 Interventional Accepts healthy volunteers

The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine

NCT06853665
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Autism, Autism Spectrum Disorder
Interventions
Adderall XR (mixed salts amphetamine), Placebo
Drug
Lead sponsor
Gagan Joshi
Other
Eligibility
8 Years to 18 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Phase 3 Interventional Results available

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits

NCT01000064
View directory record Official record
Conditions
Traumatic Brain Injury, Attention Deficit Disorder
Interventions
Vyvanse, fMRI, Placebo
Drug · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Phase 3 Interventional Results available

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

NCT01436175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate) + Antidepressant
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
140
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 2 Interventional

Amphetamine-Enhanced Stroke Recovery

NCT01905371
View directory record Official record
Conditions
Stroke
Interventions
Dextroamphetamine, Physical Therapy, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2013 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01101022
View directory record Official record
Conditions
ADHD Specifically With Executive Function Impairment
Interventions
SPD489, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
39
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 21, 2026, 5:04 PM EDT
Terminated Phase 4 Interventional Results available

Addressing Cognitive Fog in Long-COVID-19 Patients

NCT05597722
View directory record Official record
Conditions
Cognitive Impairment, Long COVID
Interventions
Digital cognitive behavioral intervention-RxWell, Amphetamine-Dextroamphetamine
Behavioral · Drug
Lead sponsor
Eva Szigethy
Other
Eligibility
21 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 3 Interventional

ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD

NCT00557960
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Mixed salts of a single-entity amphetamine, Atomoxetine hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
19 Years to 25 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 4 Interventional Results available

Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation

NCT01924429
View directory record Official record
Conditions
ADHD
Interventions
Lisdexamfetamine
Drug
Lead sponsor
Jeffrey Newcorn
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)

NCT04647903
View directory record Official record
Conditions
ADHD, Narcolepsy
Interventions
ADAIR 10 mg IR tablets, d-amphetamine sulfate, Placebo
Drug
Lead sponsor
Vallon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 21, 2026, 5:04 PM EDT
Completed No phase listed Observational

Sustained Release d-Amphetamine & Buprenorphine on Drug Seeking Behavior in Opioid & Cocaine Dependent Individuals

NCT00429767
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Cocaine Abuse or Dependence
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

NCT02635035
View directory record Official record
Conditions
Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)

NCT04077437
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Therapy, Midomafetamine, Placebo
Behavioral · Drug
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Boulder, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 21, 2026, 5:04 PM EDT
Not listed Not applicable Interventional

A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence

NCT01899313
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
CBT- based SMS text messaging intervention, CBT group therapy
Behavioral
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
2
States / cities
Lafayette, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Buspirone as a Candidate Medication for Methamphetamine Abuse

NCT01843205
View directory record Official record
Conditions
Methamphetamine Dependence, Methamphetamine Abuse
Interventions
Methamphetamine, Placebo
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence

NCT00421603
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Adderall-XR and Topiramate, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Not applicable Interventional

Neurocognitive Empowerment for Addiction Treatment (NEAT) in Opioid Use Disorder and Amphetamine Use Disorder

NCT03922646
View directory record Official record
Conditions
Opioid-use Disorder, Amphetamine Use Disorders
Interventions
Neurocognitive Empowerment for Addiction Treatment (NEAT), Active Control
Behavioral
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 3 Interventional

Epigenetics and MDMA-Assisted Psychotherapy for PTSD

NCT06189027
View directory record Official record
Conditions
PTSD
Interventions
MDMA, Psychotherapy
Drug · Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Recruiting Phase 2 Interventional

Phentermine's Impact on Treatment in Teens

NCT07282340
View directory record Official record
Conditions
Childhood Obesity
Interventions
Phentermine, Placebo
Drug
Lead sponsor
Russell McCulloh, MD
Network
Eligibility
12 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Wilmington, Delaware • Louisville, Kentucky • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Factors Affecting Methamphetamine and Opiates Drug Testing

NCT01736332
View directory record Official record
Conditions
Opiates, Healthy
Interventions
Vicks VapoInhaler, Poppy seeds
Drug · Other
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of MDMA on Startle Response

NCT03181763
View directory record Official record
Conditions
Startle Response
Interventions
Placebo, Midomafetamine, Acoustic startle
Drug · Behavioral
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
21 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD

NCT01711021
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
d-Amphetamine Transdermal Patch, Placebo patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Irvine, California • Miami, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 1 Interventional Results available

Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia

NCT01457339
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Glendale, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 21, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence

NCT02034201
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Lisdexamfetamine, Placebo
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 21, 2026, 5:04 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Hospital-Based Contingency Management

NCT05515757
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Mobile-app based contingency management
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 21, 2026, 5:04 PM EDT